Published in Hepatitis Weekly, December 9th, 2002
Pegasys is Roche's pegylated interferon alfa-2a for hepatitis C treatment that has received FDA approval. The program will provide samples to physicians to treat approximately 15,000 patients over the first 12 weeks of therapy.
After this point, responding patients will seek public or private reimbursement to complete the course of therapy. The Pegasys samples will be distributed from Priority Healthcare's Grove City, Ohio, distribution facility.
Priority Healthcare Corp. is a national...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly